Lung Cancer

Basic Overview

Lung cancer is the leading cause of cancer-related death globally and in China, classified into two major subtypes: non-small cell lung cancer (NSCLC, 80-85% of cases, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and small cell lung cancer (SCLC, 15-20% of cases, highly aggressive and neuroendocrine-derived).

Etiology: Tobacco smoking is the dominant risk factor (responsible for ~85% of cases), with additional contributors including ambient air pollution, occupational carcinogen exposure, family history, chronic obstructive pulmonary disease (COPD), and radon exposure. East Asian patients with lung adenocarcinoma have a significantly higher rate of targetable driver mutations (50-60% EGFR mutation rate, vs. 10-15% in Western populations).
Clinical Manifestations: Early-stage lung cancer is mostly asymptomatic. Advanced disease presents with persistent cough, hemoptysis, chest pain, dyspnea, unintended weight loss, hoarseness, and paraneoplastic syndromes. Brain and bone metastases are common at late stages.
Diagnosis: Low-dose computed tomography (LDCT) is the gold standard for population-based screening. Definitive diagnosis requires histopathological confirmation via biopsy, with enhanced chest CT and PET-CT for staging. Comprehensive molecular profiling (EGFR, ALK, ROS1, KRAS, MET, RET, etc.) is mandatory for advanced NSCLC to guide targeted therapy.

Standard Treatment Modalities

Early-Stage NSCLC (Stage I-II): Surgical resection is the curative gold standard, with video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RATS) as the first-line minimally invasive approaches. Adjuvant chemotherapy, targeted therapy, or immunotherapy is indicated for high-risk patients.
Locally Advanced NSCLC (Stage III): For resectable disease, neoadjuvant chemoimmunotherapy followed by surgery and adjuvant therapy is standard.
Advanced/Metastatic NSCLC (Stage IV): Precision therapy is the core of management. For driver mutation-positive disease, tyrosine kinase inhibitors (TKIs) are first-line. For driver-negative disease, chemotherapy combined with immune checkpoint inhibitors (ICIs) or dual immunotherapy is standard.
SCLC: For limited-stage disease, concurrent chemoradiotherapy plus prophylactic cranial irradiation (PCI) is standard. For extensive-stage disease, first-line treatment is platinum-based chemotherapy combined with ICIs.

Core Advantages of Treatment in China

World-Leading Precision Targeted Therapy System

: Leveraging the high prevalence of targetable driver mutations in Chinese patients, Chinese pharmaceutical companies have developed a full spectrum of domestically produced TKIs for EGFR-mutant NSCLC, with superior intracranial activity against brain metastases and equivalent efficacy to imported agents at 1/3 to 1/5 the cost.

Unmatched Minimally Invasive Surgical Volume and Expertise

: China performs the highest number of VATS and RATS lung cancer procedures globally. Top-tier thoracic surgery centers complete over 10,000 minimally invasive lung resections annually, with a 5-year overall survival (OS) rate of over 90% for stage I disease, on par with the world’s leading institutions. Surgeons have unparalleled experience in complex cases, including sleeve lobectomy for locally advanced disease and sublobar resection for ground-glass nodules.

Innovative and Accessible Immunotherapy

: Domestic PD-1/PD-L1 inhibitors have received regulatory approval for first- and second-line lung cancer indications, with large-scale Chinese clinical trials confirming non-inferior efficacy to imported agents. The cost of domestic immunotherapy is only 1/4 to 1/6 of that in the U.S., making it accessible to over 80% of advanced lung cancer patients in China.

Exceptional Cost-Effectiveness

: The total cost of lung cancer treatment in China is only 1/4 to 1/7 of that in the U.S. or Europe, with high-quality domestic surgical devices, chemotherapeutics, targeted agents, and immunotherapies available at a fraction of the cost of imported products.